Hormonal
Triple agonists (GLP-1R/GIPR/GCGR) such as retatrutide achieve greater weight loss than dual agonists by combining satiety signals with increased energy expenditure.
For severe obesity, the newest class of drugs (triple agonists like retatrutide) targets three hormones to maximize weight loss, achieving up to 24% body weight reduction in clinical trials. This is higher than dual-agonist drugs. These are weekly injections. They are currently in clinical development/trials for broader approval. Discuss with your doctor if you are a candidate for these advanced therapies.
Triagonists, such as retatrutide and peptide 20, have shown even greater efficacy in both preclinical and clinical studies... The synergism of activating the three receptors results in better outcomes in weight, glycemic, and metabolic control (10–13, 38).
Why this rating
Based on Phase II clinical trial data for retatrutide showing unprecedented weight loss percentages.
Source
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Qingtong Zhou et al. · The Annual Review of Pharmacology and Toxicology · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →